SIM0500 for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called SIM0500 for individuals with relapsed or refractory multiple myeloma, a type of blood cancer. Researchers aim to assess the treatment's safety and effectiveness and determine the optimal dosage. Participants will receive SIM0500 until their disease progresses or they can no longer tolerate it. Those who have exhausted all standard treatments for this condition without success and have a life expectancy of at least 12 weeks may be suitable candidates. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that SIM0500 is likely to be safe for humans?
Research shows that SIM0500 is undergoing safety testing for relapsed or refractory multiple myeloma. In these studies, SIM0500 attaches to specific proteins on cancer cells, aiding the immune system in identifying and destroying them. As SIM0500 is in early testing stages, detailed safety information remains limited. Treatments at this stage generally focus on assessing drug tolerance. Side effects and the body's response to the drug are closely monitored. The trial also evaluates the duration the treatment can be administered without excessive harm. Participants may discontinue the treatment if it becomes too challenging to tolerate or if they choose to exit the study.12345
Why do researchers think this study treatment might be promising?
SIM0500 is unique because it targets multiple myeloma using a novel mechanism that differs from traditional therapies like proteasome inhibitors and immunomodulatory drugs. Unlike these standard treatments, which often focus on disrupting cancer cell growth indirectly, SIM0500 works by directly interfering with specific proteins that are essential for the survival of myeloma cells. This innovative approach not only promises to be more efficient in eliminating cancer cells but also may reduce some of the side effects associated with existing treatments. Researchers are particularly excited about SIM0500 because it could represent a new generation of myeloma therapies that offer improved outcomes for patients.
What evidence suggests that SIM0500 might be an effective treatment for Multiple Myeloma?
Research has shown that SIM0500, the treatment under study in this trial, is a promising option for relapsed or refractory multiple myeloma, a type of blood cancer. As a tri-specific T-cell engager, it helps the immune system identify and destroy cancer cells. This treatment targets specific proteins on multiple myeloma cells, potentially allowing it to work even when other drugs fail. Although still in early testing, SIM0500 is considered a potentially leading option for this challenging condition. Initial results suggest it could offer new hope for patients who haven't responded to other treatments.14678
Are You a Good Fit for This Trial?
This trial is for adults over 18 with relapsed or refractory multiple myeloma who have not responded to standard treatments. Participants must be expected to live at least 12 weeks, be relatively active (ECOG score of 0 or 1), and have good blood, liver, and kidney function.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Part 1: SIM0500 is administered to determine the maximum tolerated dose
Dose Optimization
Part 2: SIM0500 is administered to optimize dosing based on Part 1 results
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- SIM0500
Trial Overview
The study tests SIM0500 in two parts: first, finding the right dose; second, confirming that dose's effectiveness. It's an open-label trial where everyone gets SIM0500 until their disease worsens, they experience bad side effects, withdraw consent or the study ends.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
SIM0500 is already approved in United States, China for the following indications:
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jiangsu Simcere Pharmaceutical Co., Ltd.
Lead Sponsor
Ren Jinsheng
Jiangsu Simcere Pharmaceutical Co., Ltd.
Chief Executive Officer since 2004
Bachelor's degree from Shanxi College of Finance and Economics, EMBA from China Europe International Business School
Tang Renhong
Jiangsu Simcere Pharmaceutical Co., Ltd.
Chief Medical Officer since 2022
MD
Shanghai Xianxiang Medical Technology Co., Ltd.
Collaborator
Shanghai Xianxiang Medical Technology Co., Ltd.
Industry Sponsor
Citations
1.
ashpublications.org
ashpublications.org/blood/article/144/Supplement%201/3381.2/529884/A-Phase-I-First-in-Human-Open-Label-Trial-toA Phase I First-in-Human, Open-Label Trial to Investigate the ...
SIM0500 is an IgG4-based tri-specific T-cell engager that consists of a CD3-specific single-chain Fv flanked by anti-BCMA and anti-GPRC5D antibodies.
Simcere Zaiming Announces First Patient Dosed in the US ...
SIM0500 stands as a potentially best-in-class candidate, poised to offer novel therapeutic options for solving drug resistance encountered in ...
Simcere Zaiming Announces First Patient Dosed in the US ...
SIM0500 stands as a potentially best-in-class candidate, poised to offer novel therapeutic options for solving drug resistance encountered in ...
Study of SIM0500 Alone in Participants With Relapsed or ...
A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500
Study of SIM0500 Alone in Participants With Relapsed or ...
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in ...
Poster Abstracts 654.Multiple Myeloma
SIM0500 binds to human T-cells through CD3, and to MM cells that expresses BCMA and/or GPRC5D, thereby recruiting activated T cells to kill BCMA or GPRC5D ...
7.
mountsinai.org
mountsinai.org/clinical-trials/study-of-sim0500-alone-in-participants-with-relapsed-refractory-multiple-myelomaStudy of SIM0500 Alone in Participants With Relapsed or ...
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult ...
SIM-0500 - Drug Targets, Indications, Patents
This drug is intended for patients with relapsed or refractory multiple myeloma (MM), currently undergoing Phase I clinical trials in China and the USA. SIM0500 ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.